Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease

Neurobiology of Disease

Volumn 27, Issue 1, 2007, Pages 11-23

  Ding, Yunmin ^a   Restrepo, Jacqueline ^a   Won, Lisa ^a   Hwang, Dong Youn ^b   Kim, Kwang Soo ^b   Kang, Un Jung ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

Aphakia mouse; Dyskinesia; FosB; l DOPA; Parkinson's disease; Striatum

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; AMANTADINE; AMPHETAMINE; BENSERAZIDE; BUSPIRONE; DOPAMINE RECEPTOR STIMULATING AGENT; IFENPRODIL; LEVODOPA; PREPRODYNORPHIN; PREPROENKEPHALIN; QUINPIROLE; SODIUM CHLORIDE; TRANSCRIPTION FACTOR FOSB;

AKINESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; APHAKIA; ARTICLE; CONTROLLED STUDY; DYSKINESIA; GENETIC MODEL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; ZONA INCERTA;

AFFERENT PATHWAYS; ANIMALS; ANTIPARKINSON AGENTS; APHAKIA; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYNORPHINS; DYSKINESIA, DRUG-INDUCED; ENKEPHALINS; LEVODOPA; MICE; MICE, INBRED C57BL; MICE, NEUROLOGIC MUTANTS; PARKINSONIAN DISORDERS; PROTEIN PRECURSORS; PROTO-ONCOGENE PROTEINS C-FOS; SUBSTANTIA NIGRA;

EID: 34250362343     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2007.03.013     Document Type: Article

References (74)

1. Andersson M., Hilbertson A., and Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6 (1999) 461-474
2. Andersson M., Konradi C., and Cenci M.A. cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J. Neurosci. 21 (2001) 9930-9943
3. Barneoud P., Descombris E., Aubin N., and Abrous D.N. Evaluation of simple and complex sensorimotor behaviours in rats with a partial lesion of the dopaminergic nigrostriatal system. Eur. J. Neurosci. 12 (2000) 322-336
4. Benazzouz A., Tai C.H., Meissner W., Bioulac B., Bezard E., and Gross C. High-frequency stimulation of both zona incerta and subthalamic nucleus induces a similar normalization of basal ganglia metabolic activity in experimental parkinsonism. FASEB J. 18 (2004) 528-530
5. Bibbiani F., Oh J.D., Petzer J.P., Castagnoli Jr. N., Chen J.F., Schwarzschild M.A., and Chase T.N. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp. Neurol. 184 (2003) 285-294
6. Blanchard R.J., Hebert M.A., Dulloog L., Kaawaloa N., Nishimura O., and Blanchard D.C. Acute cocaine effects on stereotype and defense: an ethoexperimental approach. Neurosci. Biobehav. Rev. 23 (1998) 179-188
7. Blanchet P.J., Calon F., Martel J.C., Bdard P.J., Di Paolo T., Walters R.R., and Piercey M.F. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J. Pharmacol. Exp. Ther. 272 (1995) 854-859
8. Blanchet P.J., Konitsiotis S., and Chase T.N. Amantadine reduces levodopa-induced dyskinesias in Parkinsonian monkeys. Mov. Disord. 13 (1998) 798-802
9. Boyce S., Rupniak N.M., Steventon M.J., and Iversen S.D. Characterisation of dyskinesias induced by l-DOPA in MPTP-treated squirrel monkeys. Psychopharmacology (Berl) 102 (1990) 21-27
10. Boyce S., Clarke C.E., Luquin R., Peggs D., Robertson R.G., Mitchell I.J., Sambrook M.A., and Crossman A.R. Induction of chorea and dystonia in Parkinsonian primates. Mov. Disord. 5 (1990) 3-7
11. Breit S., Bouali-Benazzouz R., Benabid A.L., and Benazzouz A. Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal activity of the pedunculopontine nucleus, which is reversed by the lesion of the subthalamic nucleus in the rat. Eur. J. Neurosci. 14 (2001) 1833-1842
12. Carlson J.D., Pearlstein R.D., Buchholz J., Iacono R.P., and Maeda G. Regional metabolic changes in the pedunculopontine nucleus of unilateral 6-hydroxydopamine Parkinson's model rats. Brain Res. 828 (1999) 12-19
13. Carta M., Lindgren H.S., Lundblad M., Stancampiano R., Fadda F., and Cenci M.A. Role of striatal l-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem. 96 (2006) 1718-1727
14. Cenci M.A. Transcription factors involved in the pathogenesis of l-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids 23 (2002) 105-109
15. Cenci M.A., Lee C.S., and Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10 (1998) 2694-2706
16. Cenci M.A., Whishaw I.Q., and Schallert T. Animal models of neurological deficits: how relevant is the rat?. Nat. Rev., Neurosci. 3 (2002) 574-579
17. Chang J.W., Wachtel S.R., Young D., and Kang U.J. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88 (1999) 617-628
18. Clarke C.E., Boyce S., Robertson R.G., Sambrook M.A., and Crossman A.R. Drug-induced dyskinesia in primates rendered hemi-Parkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J. Neurol. Sci. 90 (1989) 307-314
19. Corda M.G., Piras G., Lecca D., Fernandez-Teruel A., Driscoll P., and Giorgi O. The psychogenetically selected Roman rat lines differ in the susceptibility to develop amphetamine sensitization. Behav. Brain Res. 157 (2005) 147-156
20. Del Dotto P., Pavese N., Gambaccini G., Bernardini S., Metman L.V., Chase T.N., and Bonuccelli U. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov. Disord. 16 (2001) 515-520
21. Doucet J.P., Nakabeppu Y., Bedard P.J., Hope B.T., Nestler E.J., Jasmin B.J., Chen J.S., Iadarola M.J., St-Jean M., Wigle N., Blanchet P., Grondin R., and Robertson G.S. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur. J. Neurosci. 8 (1996) 365-381
22. Fleming S.M., Salcedo J., Fernagut P.O., Rockenstein E., Masliah E., Levine M.S., and Chesselet M.F. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci. 24 (2004) 9434-9440
23. Fox S.H., Henry B., Hill M., Crossman A., and Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. 17 (2002) 1180-1187
24. Franklin, K.B.J., Paxinos, G., 1997. The Mouse Brain in Stereotaxic Coordinates. Academic Press, Inc., San Diego, CA.
25. Gardoni F., Picconi B., Ghiglieri V., Polli F., Bagetta V., Bernardi G., Cattabeni F., Di Luca M., and Calabresi P. A critical interaction between NR2B and MAGUK in l-DOPA induced dyskinesia. J. Neurosci. 26 (2006) 2914-2922
26. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma J., and Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990) 1429-1432
27. Gerfen C.R., McGinty J.F., and Young W.S. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J. Neurosci. 11 (1991) 1016-1031
28. Henry B., Crossman A.R., and Brotchie J.M. Characterization of enhanced behavioral responses to l-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 151 (1998) 334-342
29. Hwang D.Y., Ardayfio P., Kang U.J., Semina E.V., and Kim K.S. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res. Mol. Brain Res. 114 (2003) 123-131
30. Hwang D.Y., Fleming S.M., Ardayfio P., Moran-Gates T., Kim H., Tarazi F.I., Chesselet M.F., and Kim K.S. 3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J. Neurosci. 25 (2005) 2132-2137
31. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 45 (1995) S6-S12
32. Johnson R.E., Schallert T., and Becker J.B. Akinesia and postural abnormality after unilateral dopamine depletion. Behav. Brain Res. 104 (1999) 189-196
33. Johnston T.H., Lee J., Gomez-Ramirez J., Fox S.H., and Brotchie J.M. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease. Exp. Neurol. 191 (2005) 243-250
34. Kang, U.J., Ding, Y., Rokosik, S., Koh, H., 2005. Fos-B expression in the penduncopontine nucleus correlates with the persistence of I-dopa-induced dyskinesia in mice with unilateral 6-hydroxydopamine lesions Program No. 566.12.2005. Society for Neuroscience, Washington, DC.
35. Kase H., Aoyama S., Ichimura M., Ikeda K., Ishii A., Kanda T., Koga K., Koike N., Kurokawa M., Kuwana Y., Mori A., Nakamura J., Nonaka H., Ochi M., Saki M., Shimada J., Shindou T., Shiozaki S., Suzuki F., Takeda M., Yanagawa K., Richardson P.J., Jenner P., Bedard P., Borrelli E., Hauser R.A., and Chase T.N. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology 61 (2003) S97-S100
36. Kovoor A., Seyffarth P., Ebert J., Barghshoon S., Chen C.K., Schwarz S., Axelrod J.D., Cheyette B.N., Simon M.I., Lester H.A., and Schwarz J. D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. J. Neurosci. 25 (2005) 2157-2165
37. Lee C.S., Cenci M.A., Schulzer M., and Bjorklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 123 Pt. 7 (2000) 1365-1379
38. Linazasoro G. New ideas on the origin of l-DOPA-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol. Sci. 26 (2005) 391-397
39. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., and Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15 (2002) 120-132
40. Lundblad M., Vaudano E., and Cenci M.A. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J. Neurochem. 84 (2003) 1398-1410
41. Lundblad M., Picconi B., Lindgren H., and Cenci M.A. A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 16 (2004) 110-123
42. Lundblad M., Usiello A., Carta M., Hakansson K., Fisone G., and Cenci M.A. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp. Neurol. 194 (2005) 66-75
43. Luquin M.R., Laguna J., and Obeso J.A. Selective D2 receptor stimulation induces dyskinesia in Parkinsonian monkeys. Ann. Neurol. 31 (1992) 551-554
44. Luquin M.R., Scipioni O., Vaamonde J., Gershanik O., and Obeso J.A. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov. Disord. 7 (1992) 117-124
45. Marconi R., Lefebvre-Caparros D., Bonnet A.M., Vidailhet M., Dubois B., and Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov. Disord. 9 (1994) 2-12
46. Marin C., Rodriguez-Oroz M.C., and Obeso J.A. Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?. Exp. Neurol. 197 (2006) 269-274
47. Mehta A., Thermos K., and Chesselet M.F. Increased behavioral response to dopaminergic stimulation of the subthalamic nucleus after nigrostriatal lesions. Synapse 37 (2000) 298-307
48. Mena-Segovia J., Bolam J.P., and Magill P.J. Pedunculopontine nucleus and basal ganglia: distant relatives or part of the same family?. Trends Neurosci. 27 (2004) 585-588
49. Monville C., Torres E.M., and Dunnett S.B. Validation of the l-DOPA-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res. Bull. 68 (2005) 16-23
50. Morris B.J., Hollt V., and Herz A. Dopaminergic regulation of striatal proenkephalin mRNA and prodynorphin mRNA: contrasting effects of D1 and D2 antagonists. Neuroscience 25 (1988) 525-532
51. Morris B.J., Herz A., and Hollt V. Localization of striatal opioid gene expression, and its modulation by the mesostriatal dopamine pathway: an in situ hybridization study. J. Mol. Neurosci. 1 (1989) 9-18
52. Nadjar A., Brotchie J.M., Guigoni C., Li Q., Zhou S.B., Wang G.J., Ravenscroft P., Georges F., Crossman A.R., and Bezard E. Phenotype of striatofugal medium spiny neurons in Parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia. J. Neurosci. 26 (2006) 8653-8661
53. Nandi D., Aziz T.Z., Giladi N., Winter J., and Stein J.F. Reversal of akinesia in experimental Parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus. Brain 125 (2002) 2418-2430
54. Nash J.E., Fox S.H., Henry B., Hill M.P., Peggs D., McGuire S., Maneuf Y., Hille C., Brotchie J.M., and Crossman A.R. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 165 (2000) 136-142
55. Nunes I., Tovmasian L.T., Silva R.M., Burke R.E., and Goff S.P. Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4245-4250
56. Pahapill P.A., and Lozano A.M. The pedunculopontine nucleus and Parkinson's disease. Brain 123 Pt. 9 (2000) 1767-1783
57. Pahwa R., Factor S.A., Lyons K.E., Ondo W.G., Gronseth G., Bronte-Stewart H., Hallett M., Miyasaki J., Stevens J., and Weiner W.J. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 (2006) 983-995
58. Pavon N., Martin A.B., Mendialdua A., and Moratalla R. ERK phosphorylation and FosB expression are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol. Psychiatry 59 (2006) 64-74
59. Phillips J.M., Latimer M.P., Gupta S., Winn P., and Brown V.J. Excitotoxic lesions of the subthalamic nucleus ameliorate asymmetry induced by striatal dopamine depletion in the rat. Behav. Brain Res. 90 (1998) 73-77
60. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., and Calabresi P. Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat. Neurosci. 6 (2003) 501-506
61. Plaha P., Ben-Shlomo Y., Patel N.K., and Gill S.S. Stimulation of the caudal zona incerta is superior to stimulation of the subthalamic nucleus in improving contralateral parkinsonism. Brain 129 (2006) 1732-1747
62. Rahman Z., Schwarz J., Gold S.J., Zachariou V., Wein M.N., Choi K.H., Kovoor A., Chen C.K., DiLeone R.J., Schwarz S.C., Selley D.E., Sim-Selley L.J., Barrot M., Luedtke R.R., Self D., Neve R.L., Lester H.A., Simon M.I., and Nestler E.J. RGS9 modulates dopamine signaling in the basal ganglia. Neuron 38 (2003) 941-952
63. Salin P., Hajji M.D., and Kerkerian-le Goff L. Bilateral 6-hydroxydopamine-induced lesion of the nigrostriatal dopamine pathway reproduces the effects of unilateral lesion on substance P but not on enkephalin expression in rat basal ganglia. Eur. J. Neurosci. 8 (1996) 1746-1757
64. Smidt M.P., Smits S.M., Bouwmeester H., Hamers F.P., Van Der Linden A.J., Hellemons A.J., Graw J., and Burbach J.P. Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3. Development 131 (2004) 1145-1155
65. Smits S.M., Mathon D.S., Burbach J.P., Ramakers G.M., and Smidt M.P. Molecular and cellular alterations in the Pitx3-deficient midbrain dopaminergic system. Mol. Cell. Neurosci. 30 (2005) 352-363
66. Steece-Collier K., Chambers L.K., Jaw-Tsai S.S., Menniti F.S., and Greenamyre J.T. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp. Neurol. 163 (2000) 239-243
67. Steiner H., and Gerfen C.R. Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp. Brain Res. 123 (1998) 60-76
68. Truong L., Allbutt H., Kassiou M., and Henderson J.M. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions. Behav. Brain Res. 169 (2006) 1-9
69. van den Munckhof P., Luk K.C., Ste-Marie L., Montgomery J., Blanchet P.J., Sadikot A.F., and Drouin J. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 130 (2003) 2535-2542
70. van den Munckhof P., Gilbert F., Chamberland M., Levesque D., and Drouin J. Striatal neuroadaptation and rescue of locomotor deficit by l-DOPA in aphakia mice, a model of Parkinson's disease. J. Neurochem. 96 (2006) 160-170
71. Winkler C., Kirik D., Bjorklund A., and Cenci M.A. l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 10 (2002) 165-186
72. Woodlee M.T., Asseo-Garcia A.M., Zhao X., Liu S.J., Jones T.A., and Schallert T. Testing forelimb placing "across the midline" reveals distinct, lesion-dependent patterns of recovery in rats. Exp. Neurol. 191 (2005) 310-317
73. Xiao D., Bastia E., Xu Y.H., Benn C.L., Cha J.H., Peterson T.S., Chen J.F., and Schwarzschild M.A. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J. Neurosci. 26 (2006) 13548-13555
74. Zhuang X., Oosting R.S., Jones S.R., Gainetdinov R.R., Miller G.W., Caron M.G., and Hen R. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 1982-1987